Amar Sawhney

Amar brings deep domain experience to the board of directors, having created, developed and commercialized hydrogel-based medical devices and drugs to address unmet clinical needs across ophthalmology, neurosurgery, radiation oncology, cardiovascular interventions, and women’s health, to name a few.

Amar is currently the Chairman, Founder and CEO of Instylla, which is developing liquid embolics for interventional procedures; and Rejoni, which is developing products to prevent intrauterine scarring. He is also a partner at Incept LLC and Pramand LLC, two health innovation accelerators he has co-founded. Prior to this, he was founder and CEO of Ocular Therapeutix (OCUL), Founder and Chairman of Augmenix (acquired by Boston Scientific), CEO of Confluent Surgical (acquired by Covidien) and co-founder of Focal (FOCL; acquired by Genzyme) and Access Closure (acquired by Cardinal Health). Dr. Sawhney’s innovations are the subject of over 120 issued and pending patents.

He holds a B.Tech. degree in chemical engineering from the Indian Institute of Technology, Delhi India and an M.S./Ph.D. degree in chemical engineering from the University of Texas at Austin.